Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Down 77.5% in December

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a large drop in short interest in the month of December. As of December 15th, there was short interest totaling 8,073 shares, a drop of 77.5% from the November 30th total of 35,860 shares. Based on an average daily volume of 67,704 shares, the short-interest ratio is presently 0.1 days. Approximately 0.5% of the company’s shares are sold short. Approximately 0.5% of the company’s shares are sold short. Based on an average daily volume of 67,704 shares, the short-interest ratio is presently 0.1 days.

Catheter Precision Price Performance

Shares of NYSEAMERICAN VTAK traded down $0.03 during midday trading on Thursday, hitting $1.78. 18,839 shares of the company traded hands, compared to its average volume of 52,559. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.46 and a quick ratio of 0.46. The stock has a 50-day moving average price of $2.27 and a 200 day moving average price of $3.18. Catheter Precision has a 12-month low of $1.49 and a 12-month high of $15.68.

Catheter Precision (NYSEAMERICAN:VTAK) last released its quarterly earnings results on Thursday, November 13th. The company reported ($1.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($26.60) by $24.90. Catheter Precision had a negative net margin of 2,333.29% and a negative return on equity of 208.54%. The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $1.20 million. On average, equities research analysts forecast that Catheter Precision will post -8.9 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Catheter Precision

A hedge fund recently raised its stake in Catheter Precision stock. Armistice Capital LLC boosted its position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) by 94.3% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 250,965 shares of the company’s stock after acquiring an additional 121,800 shares during the quarter. Armistice Capital LLC owned about 2.84% of Catheter Precision worth $86,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 20.34% of the company’s stock.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.